Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Stroke. 2017 Jul 5;48(8):2158–2163. doi: 10.1161/STROKEAHA.116.016254

Table 3.

Comparison of 30-day recurrent stroke risk by demographic, clinical, serologic, and imaging factors

Variable Recurrent stroke
(n=20)
No recurrent
stroke (n=79)
P-value
Mean age (SD) in years 65.9 (10.6) 68.8 (11.3) 0.303
Male, n (%) 14 (70.0) 37 (46.8) 0.068
Race, n (%) 0.445
  White 7 (35.0) 31 (39.2)
  African-American 10 (50.0) 43 (54.4)
  Other 3 (15.0) 5 (6.3)
Hypertension, n (%) 16 (80.0) 65 (82.3) 0.813
Diabetes mellitus, n (%) 8 (40.0) 49 (62.0) 0.075
Hemoglobin A1c, n (%) 0.894
    <5.7%, n (%) 6 (30.0) 22 (27.8)
    5.8–7.9%, n (%) 9 (45.0) 33 (41.8)
    >7.9%, n (%) 5 (25.0) 24 (30.4)
Dyslipidemia, n (%) 19 (95.0) 68 (86.1) 0.275
LDL level, n (%) 0.313
    <70 mg/dL, n (%) 4 (20.0) 16 (20.3)
    70–100 mg/dL, n (%) 4 (20.0) 29 (36.7)
    >100 mg/dL, n (%) 12 (60.0) 34 (43.0)
Coronary artery disease, n (%) 5 (25.0) 17 (21.5) 0.738
Prior history of ischemic stroke or TIA, n (%) 8 (40.0) 37 (46.8) 0.583
Current smoking, n (%) 3 (15.0) 20 (25.3) 0.329
Statin therapy, n (%) 9 (45.0) 44 (55.7) 0.392
NIHSS score >1, n (%) 13 (65.0) 49 (62.0) 0.806
Vertebrobasilar location, n (%) 5 (25.0) 27 (34.2) 0.433
Severe stenosis, n (%) 16 (80.0) 53 (67.1) 0.262
Prior infarcts in the territory, n (%) 9 (45.0) 31 (39.7) 0.670
Aggressive medical management, n (%) 10 (50.0) 38 (48.1) 0.879
Dual anti-platelet therapy, n (%) 15 (75.0) 52 (65.8) 0.433
High-dose statin therapy, n (%) 14 (70.0) 51 (64.6) 0.647